1月5日，迈得医疗涨5.22%，截至发稿，报16.13元/股，成交3776.56万元，换手率1.45%，总市值26.81 亿元。 资料显示，迈得医疗工业设备股份有限公司位于浙江省玉环市沙门镇滨港工业城，成立日期2003年3月 10日，上市日期2019年12月3日，公司主营业务涉及医用耗材智能装备的研发、生产、销售和服务。主 营业务收入构成为：安全输注类48.75%，血液净化类26.27%，其他24.98%。 从迈得医疗十大流通股东角度 数据显示，华夏基金旗下1只基金位居迈得医疗十大流通股东。华夏行业景气混合A（003567）三季度 减持106.61万股，持有股数260.36万股，占流通股的比例为1.57%。根据测算，今日浮盈赚取约208.29万 元。 华夏行业景气混合A（003567）基金经理为钟帅。 截至发稿，钟帅累计任职时间5年163天，现任基金资产总规模132.6亿元，任职期间最佳基金回报 185.99%， 任职期间最差基金回报0.5%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不 ...

证券之星消息，截至2025年12月26日收盘，迈得医疗(688310)报收于15.47元，下跌1.59%，换手率 1.46%，成交量2.43万手，成交额3800.12万元。 12月26日的资金流向数据方面，主力资金净流入315.12万元，占总成交额8.29%，游资资金净流入 234.22万元，占总成交额6.16%，散户资金净流出549.35万元，占总成交额14.46%。 近5日资金流向一览见下表： 迈得医疗2025年三季报显示，前三季度公司主营收入2.25亿元，同比上升2.31%；归母净利润883.67万 元，同比上升15.82%；扣非净利润-127.85万元，同比下降526.58%；其中2025年第三季度，公司单季度 主营收入8364.3万元，同比上升54.38%；单季度归母净利润279.16万元，同比上升224.07%；单季度扣 非净利润123.64万元，同比上升118.23%；负债率29.86%，投资收益16.76万元，财务费用-52.36万元， 毛利率40.19%。迈得医疗（688310）主营业务：医用耗材智能装备的研发、生产、销售和服务,有效整 合医疗器械产品工艺、自动化、软件等方面的技术,形成独特 ...

Core Viewpoint - Midea Medical's stock price dropped by 5% to 15.95 CNY per share, with a total market capitalization of 2.651 billion CNY as of the report date [1] Company Overview - Midea Medical Industrial Equipment Co., Ltd. is located in Yuhuan City, Zhejiang Province, established on March 10, 2003, and listed on December 3, 2019 [1] - The company's main business involves the research, production, sales, and service of medical consumables and intelligent equipment [1] - Revenue composition: Safety infusion products account for 48.75%, blood purification products 26.27%, and other products 24.98% [1] Shareholder Information - Among the top ten circulating shareholders, one fund from Huaxia Fund holds shares in Midea Medical [2] - Huaxia Industry Prosperity Mixed A (003567) reduced its holdings by 1.0661 million shares in Q3, now holding 2.6036 million shares, representing 1.57% of circulating shares [2] - Estimated floating loss for Huaxia Industry Prosperity Mixed A today is approximately 2.187 million CNY [2] Fund Manager Details - The fund manager of Huaxia Industry Prosperity Mixed A is Zhong Shuai [3] - As of the report date, Zhong Shuai has a cumulative tenure of 5 years and 125 days, with total fund assets of 13.26 billion CNY [3] - Best fund return during tenure is 169.98%, while the worst return is -5.09% [3]

Core Viewpoint - The company, Maide Medical (688310), reported a revenue of 225 million yuan for the first three quarters of 2025, reflecting a year-on-year increase of 2.31%, with a net profit of 8.84 million yuan, up 15.82% year-on-year [3] Group 1: Financial Performance - For Q3 2025, the company achieved a single-quarter revenue of 83.64 million yuan, representing a year-on-year increase of 54.38% [3] - The net profit for Q3 2025 was 2.79 million yuan, showing a significant year-on-year increase of 224.07% [3] - The company reported a gross margin of 40.19% and a debt ratio of 29.86% [3] Group 2: Product and Market Insights - The core products contributing to revenue growth include safety infusion and blood purification intelligent equipment, along with the promotion of drug-device combination intelligent equipment [1] - The company has four production lines for contact lenses, each with an annual capacity of 18 million pieces, and is currently applying for registration of daily disposable soft contact lenses [2] - The domestic contact lens market is dominated by four major international players, but there are opportunities for domestic brands as the market evolves [2] Group 3: Future Plans and Investments - The company plans to focus on its main business development, enhance its product matrix, and invest in R&D for contact lenses, product certification, and new product development [1][2] - Future investments will also target capacity expansion and integration within the supply chain [1]

Core Viewpoint - Midea Medical experienced a decline of 5.33% in stock price, reaching 19.91 CNY per share, with a total market capitalization of 3.309 billion CNY as of October 28 [1] Company Overview - Midea Medical Industrial Equipment Co., Ltd. is located in Yuhuan City, Zhejiang Province, established on March 10, 2003, and listed on December 3, 2019 [1] - The company's main business involves the research, production, sales, and service of medical consumable intelligent equipment [1] - Revenue composition includes: 48.75% from safe infusion products, 26.27% from blood purification, and 24.98% from other categories [1] Shareholder Information - Among the top circulating shareholders, one fund from Huaxia Fund holds a significant position, having reduced its holdings by 1.0661 million shares in Q3, now holding 2.6036 million shares, which is 1.57% of circulating shares [2] - The Huaxia Industry Prosperity Mixed A Fund (003567) was established on February 4, 2017, with a current scale of 7.261 billion CNY and a year-to-date return of 56.47%, ranking 837 out of 8155 in its category [2] - The fund manager, Zhong Shuai, has a tenure of 5 years and 94 days, with the best fund return during this period being 177.53% and the worst being -2.4% [2]

Group 1 - The core viewpoint of the news is that Maide Medical has seen a stock price increase of 5.16%, reaching 20.77 CNY per share, with a total market capitalization of 3.452 billion CNY [1] - Maide Medical, established on March 10, 2003, and listed on December 3, 2019, specializes in the research, production, sales, and service of medical consumables and intelligent equipment [1] - The company's main business revenue composition includes: 48.75% from safe infusion products, 26.27% from blood purification, and 24.98% from other categories [1] Group 2 - From the perspective of fund holdings, one fund under Guotai Fund has a significant position in Maide Medical, with 200,000 shares held, accounting for 1.08% of the fund's net value [2] - The Guotai Ju Li Value Flexible Allocation Mixed Fund (005746) has a current scale of 273 million CNY and has achieved a year-to-date return of 5.34% [2] - The fund's performance ranks 6799 out of 8243 in its category for the year and has a cumulative return of 46.8% since its inception [2]

Core Insights - The medical consumables intelligent equipment industry is experiencing a dual upgrade in scale and quality, driven by the transformation of the manufacturing sector and the localization of medical devices [1][2] - Midea Medical Industrial Equipment Co., Ltd. (stock code: 688310) has over 20 years of experience in the medical consumables intelligent equipment sector, focusing on technological innovation and establishing core competitiveness in areas such as safe infusion and blood purification [1][2] Industry Overview - The Chinese medical device industry is projected to reach a total scale of 1.2 trillion yuan by 2025, with high-value consumables accounting for over 30%, corresponding to a market size exceeding 360 billion yuan [2] - The blood purification product segment is expected to grow significantly, with a market size of approximately 18.7 billion yuan in 2024, reflecting a year-on-year growth of 10% due to the rising number of end-stage renal disease (ESRD) patients [2] - The number of ESRD patients in China reached 4.1259 million in 2023 and is expected to increase to 5.2713 million by 2027, driving demand for automated production equipment for dialysis consumables [2] - The pre-filled syringe market is expanding rapidly, supported by the biopharmaceutical, medical aesthetics, and vaccine sectors, with a shift from Western markets to domestic production [2] - The "14th Five-Year" medical equipment industry development plan emphasizes support for the localization of high-end medical equipment, aiming for over 50% of county-level hospitals to procure domestic CTs by 2025 [2] Company Performance - Midea Medical focuses on intelligent equipment for medical consumables, including safe infusion, blood purification, and drug-device combination solutions, offering a full chain of solutions from single machines to connected systems [3] - The company has made significant advancements in blood purification equipment, breaking foreign monopolies with its domestically produced medical dialysis equipment [3] - Despite market fluctuations and longer production cycles, the company demonstrated resilience with R&D investment reaching 17.9772 million yuan, accounting for 12.75% of revenue, an increase of 0.48 percentage points year-on-year [4] - The net cash flow from operating activities reached 110 million yuan, a substantial year-on-year increase of 243.90%, indicating improved cash flow [4] Competitive Advantages - The company possesses strong core competencies across technology, R&D, customer relations, and market presence, with 18 key technologies, including advanced solvent bonding technology that reduces glue usage by 20% [5] - Midea Medical has established long-term partnerships with leading domestic medical consumables companies and has entered the supply chains of international clients [5] - The company has maintained the highest market share in its industry for three consecutive years from 2022 to 2024, showcasing its significant first-mover advantage [5] New Business Development - Midea Medical is expanding its growth avenues through its subsidiary, Midea Shun, which is focusing on the contact lens CDMO business, addressing domestic outsourcing gaps [6] - The company is also making strides in international markets by building overseas R&D and sales networks, aiming to extend its cost and technological advantages globally [6]

Core Viewpoint - Midea Medical's stock rose by 5.79% on September 16, reaching 20.66 yuan per share, with a total market capitalization of 3.434 billion yuan [1] Company Overview - Midea Medical Industrial Equipment Co., Ltd. is located in Yuhuan City, Zhejiang Province, established on March 10, 2003, and listed on December 3, 2019. The company specializes in the research, production, sales, and service of medical consumables and intelligent equipment [1] - The main business revenue composition includes: 42.18% from safe infusion line machines, 37.90% from blood purification line machines, 14.04% from safe infusion single machines, and 5.87% from other categories [1] Fund Holdings - According to data from the top ten heavy stocks of funds, one fund under Guotai Fund holds a significant position in Midea Medical. The Guotai Value Flexible Allocation Mixed Fund (005746) held 200,000 shares in the second quarter, accounting for 1.08% of the fund's net value, ranking as the eighth largest heavy stock [2] - The fund has generated an estimated floating profit of approximately 226,000 yuan today [2] Fund Performance - The Guotai Value Flexible Allocation Mixed Fund (005746) was established on March 27, 2018, with a latest scale of 273 million yuan. Year-to-date returns are 5.47%, ranking 6623 out of 8174 in its category; the one-year return is 10.46%, ranking 6881 out of 7982; and since inception, the return is 46.99% [2] Fund Managers - The fund managers are Cheng Zhou and Cheng Yao. Cheng Zhou has a cumulative tenure of 17 years and 171 days, with a total fund asset scale of 6.594 billion yuan, achieving a best fund return of 361.33% and a worst return of -37% during his tenure [3] - Cheng Yao has a cumulative tenure of 4 years and 71 days, managing a total fund asset scale of 1.921 billion yuan, with a best fund return of 14.74% and a worst return of 3.78% during her tenure [3]

Group 1 - The core viewpoint of the news is that Maide Medical's stock has experienced a decline of 5.07%, with a current price of 19.47 CNY per share and a total market capitalization of 3.236 billion CNY [1] - Maide Medical, established on March 10, 2003, and listed on December 3, 2019, specializes in the research, production, sales, and service of medical consumables and intelligent equipment [1] - The main revenue composition of Maide Medical includes: 42.18% from safety infusion line machines, 37.90% from blood purification line machines, 14.04% from safety infusion single machines, and 5.87% from other categories [1] Group 2 - Among the top ten circulating shareholders of Maide Medical, a fund under Rongtong Fund holds a position, having reduced its holdings by 156 shares in the first quarter, now owning 2.5998 million shares, which is 1.56% of the circulating shares [2] - The Rongtong Health Industry Flexible Allocation Mixed A/B fund (000727) has a current scale of 2.074 billion CNY and has achieved a return of 23.63% this year, ranking 3072 out of 8194 in its category [2] - The fund has a one-year return of 47%, ranking 2642 out of 7963, and a cumulative return since inception of 198.7% [2]

Main Business - The company's main products include safety infusion devices and blood purification equipment, with significant revenue declines in safety infusion single machines and blood purification single machines, down 39.59% and 100.00% respectively, while blood purification continuous machines saw substantial growth [2][5][6] - The first major customer accounted for a significant portion of annual sales, with the increase in transaction amount attributed to the growth in the blood purification product business and the overall industry [2][14] Supplier Information - The company sources all standard parts externally, with a mix of self-manufactured, custom procurement, and outsourced processing for non-standard components. The total procurement amount for 2024 was 23,959.42 million yuan, a decrease of 36.99% compared to the previous year [28][29] Inventory and Contract Liabilities - The company reported that the inventory of blood purification single machines remained unsold due to production cycle delays and customer facility issues, impacting revenue recognition [11][12] - The company maintains a production model based on order fulfillment, which has led to fluctuations in sales revenue for blood purification single machines [11][12] Accounts Receivable and Long-term Receivables - The company provided details on its top five customers, including transaction amounts and payment conditions, indicating a healthy receivables situation with good recovery rates [13][15] Goodwill Impairment - There were no indications of impairment for the company's assets, as the net realizable value of blood purification single machines exceeded their costs, negating the need for inventory write-downs [12][25] Construction in Progress - The company has invested in the development of its contact lens manufacturing subsidiary, with a focus on material research and production line construction, indicating a strategic expansion into the optical sector [3][24] Market Trends - The blood dialysis medical device market in China is projected to grow steadily, with a compound annual growth rate of 5.67% from 2019 to 2023, expected to reach 51.515 billion yuan by 2030 [6][14] - The company is also expanding into the contact lens market, which is anticipated to grow significantly, with the transparent and colored contact lens markets projected to reach 161 billion yuan and 183 billion yuan respectively by 2030 [18][20]